P6487
Anti-Purinergic Receptor P2Y1 antibody produced in rabbit
affinity isolated antibody, lyophilized powder
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
IHC, WB
Citations:
7
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlebiological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
lyophilized powder
species reactivity
human, rat
technique(s)
immunohistochemistry: suitable, western blot: suitable
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... P2RY1(5028)
rat ... P2ry1(25265)
General description
Purinergic Receptor P2Y1 is a member of G protein-coupled receptors. The P2Y1 gene is mapped to human chromosome 3q25.2. It is present in the heart, blood vessels, prostate, testis, ovary, and neural tissue.
Immunogen
synthetic peptide corresponding to residues 242-258 of rat or human P2Y1.
Application
Anti-Purinergic Receptor P2Y1 antibody produced in rabbit has been used in western blotting1:200 and immunohistochemistry at a dilution of 1:50.
Biochem/physiol Actions
Purinergic Receptor P2Y1 acts as a receptor for extracellular ATP and ADP. It is essential for ADP-induced platelet activation, aggregation, and thrombosis. P2Y1 also participates in endothelial cell-based nucleotide-induced relaxation and in calcium mobilization. It serves as a potential target for the generation of new antiplatelet compounds and anti-inflammatory strategies.
Physical form
Lyophilized from phosphate buffered saline, pH 7.4, 1% bovine serum albumin and 0.05% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Milka Koupenova et al.
Frontiers in pharmacology, 9, 37-37 (2018-02-15)
Platelets are small anucleated cells present only in mammals. Platelets mediate intravascular hemostatic balance, prevent interstitial bleeding, and have a major role in thrombosis. Activation of platelet purinergic receptors is instrumental in initiation of hemostasis and formation of the hemostatic
Shara Khan et al.
Diabetologia, 57(12), 2535-2545 (2014-09-12)
There is evidence that ATP acts as an autocrine signal in beta cells but the receptors and pathways involved are incompletely understood. Here we investigate the receptor subtype(s) and mechanism(s) mediating the effects of ATP on human beta cells. We
J Simon et al.
Acta biologica Hungarica, 54(2), 191-201 (2003-10-11)
Since the first identification of P2Y receptor sequences in 1993, it has quickly become apparent that this family of the G-protein coupled receptors is very diverse. Members of this receptor family are activated extra-cellularly by a wide variety of adenosine
Anna Wilkaniec et al.
Purinergic signalling, 13(3), 347-361 (2017-05-19)
Abnormalities of alpha-synuclein (ASN), the main component of protein deposits (Lewy bodies), were observed in Parkinson's disease (PD), dementia with Lewy bodies, Alzheimer's disease, and other neurodegenerative disorders. These alterations include increase in the levels of soluble ASN oligomers in
Agnete Kirkeby et al.
Thrombosis and haemostasis, 99(4), 720-728 (2008-04-09)
The haematopoietic hormone erythropoietin (EPO) has neuroprotective properties and is currently being explored for treatment of stroke and other neurological disorders. Short-term, high-dose treatment with EPO seems to improve neurological function of stroke patients but may be associated with increased
Contenido relacionado
Datasheet
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico